Résultats de la recherche
10
Tout
Rechercher les filtres
Mot-clé
dermatology
Alumis and Kaken Pharmaceutical Announce Collaboration and Licensing Agreement for ESK-001 in Dermatology in Japan
25 mars 2025 02h30 HE
|
Alumis Inc.
Alumis and Kaken Pharmaceutical collaborate for oral next-generation TYK2 inhibitor ESK-001 in dermatology in Japan
Journey Medical Corporation Launches Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) for the Treatment of Rosacea
24 mars 2025 08h30 HE
|
Journey Medical Corporation
Initial distribution of Emrosi to pharmacies ongoing First prescriptions of Emrosi filled SCOTTSDALE, Ariz., March 24, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey...
Sitryx initiates Phase 1 clinical trial of potential disease-modifying treatment for atopic dermatitis SYX-5219
20 mars 2025 07h00 HE
|
Sitryx Therapeutics
Sitryx initiates Phase 1 clinical trial of potential disease-modifying treatment for atopic dermatitis SYX-5219 SYX-5219 is a first-in-class oral PKM2 modulator designed to drive sustained disease...
Journey Medical Corporation to Announce Year End 2024 Financial Results on March 26, 2025
19 mars 2025 16h01 HE
|
Journey Medical Corporation
SCOTTSDALE, Ariz., March 19, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or the “Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily...
Cytrellis Secures Health Canada and Saudi Food and Drug Authority Approval for ellacor® with Micro-Coring® Technology
18 mars 2025 08h05 HE
|
Cytrellis Biosystems
Cytrellis Biosystems has received approval to commercialize its groundbreaking ellacor® with Micro-Coring® technology in Canada and Saudi Arabia.
Study Reveals Lack of Physician Oversight in Missouri Medical Spas, Raising Patient Safety Concerns from ASDSA
17 mars 2025 07h00 HE
|
American Society for Dermatologic Surgery Association
Schaumburg, Ill., March 17, 2025 (GLOBE NEWSWIRE) -- A new study published in the January 2025 issue of Dermatologic Surgery – the official scientific journal of the American Society for...
Kane Biotech Secures IRB Approval to Launch Innovative DispersinB® Acne Trial
13 mars 2025 08h30 HE
|
Kane Biotech Inc.
WINNIPEG, Manitoba, March 13, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) ("Kane Biotech" or "Kane") announces today that it has received approval from the Internal Review...
Journey Medical Corporation to Participate in the 37th Annual ROTH Conference
12 mars 2025 08h30 HE
|
Journey Medical Corporation
SCOTTSDALE, Ariz., March 12, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses on selling and...
Dupixent® (dupilumab) Late-Breaking Positive Pivotal Data in Bullous Pemphigoid Presented at AAD
08 mars 2025 13h00 HE
|
Regeneron Pharmaceuticals, Inc.
Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also seen in disease severity and itch Dupixent also significantly...
Late-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in Psoriasis
08 mars 2025 09h00 HE
|
Alumis Inc.
ESK-001 demonstrated robust clinical responses and was well tolerated over 52 weeks in a Phase 2 clinical trial, presented in a late-breaker at AAD 2025